Clinical trial
Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma
NCT00384826 · Intergroupe Francophone de Cancerologie Thoracique, Other · Completed
Key facts
| NCT number | NCT00384826 |
|---|---|
| Title | Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma |
| Official title | Effect of an Early Therapeutic Permutation on the Tumoral Control of Patients Receiving in First Line a Specific Inhibitor of Tyrosin Kinase of EGFR (Erlotinib) or a Taxan-based Chemotherapy for the Treatment of Not Resecable Adenocarcinoma With Bronchiolo-alveolar. |
| Lead sponsor | Intergroupe Francophone de Cancerologie Thoracique, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma, Bronchiolo-Alveolar |
| Intervention type | Drug |
| Interventions | erlotinib, paclitaxel + carboplatine |
| Enrollment | 133 |
| Start date | Sep 1, 2006 |
| Primary completion | Feb 1, 2014 |
| Completion | Feb 1, 2014 |
| First posted | Oct 6, 2006 |
| Last update posted | Feb 16, 2015 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: